← Novartis overview

Novartis vs AbbVie: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novartis AG (NOVN.SW)

Q3 2026
▲2▼2

Novartis Q3: new drugs and deals offset generic hit and pipeline setbacks

  • New drug approvals and acquisition EU approved Itvisma gene therapy and FDA fully approved Fabhalta for kidney disease. Novartis also bought Myricx Bio for $1.5 billion, adding new treatments to its portfolio.

    These approvals and the acquisition are new positive events that can drive future sales and growth.

  • Earnings beat and pipeline progress Q2 earnings beat expectations with sales returning to growth. Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing, and licensing deals worth up to $8.1 billion plus Sironax acquisition signaled continued innovation investment.

    Earnings beat and pipeline advancements are new positive developments that support investor confidence.

  • Entresto sales plunge on generics Entresto sales plunged 50% due to generic competition, a $4 billion annual hit. This major revenue loss weighs on the stock.

    This is a new negative event that directly impacts Novartis's revenue and profitability.

  • Pipeline setbacks and governance concerns CAR-T trials paused after three deaths; pelacarsen and del-desiran failed late-stage trials; rifonebart was halted. UBS turned cautious, and top shareholder Artisan Partners demanded a board overhaul amid $39.4 billion net debt and governance concerns.

    These new negative events raise safety, efficacy, and governance issues that can hurt investor sentiment.

September 2026
▼2▲1

Pipeline failures and governance pressure hit Novartis in September

  • Late-stage trial failures Pelacarsen and del-desiran failed late-stage trials, erasing billions in potential revenue and market value, while ALS drug rifonebart was halted. These setbacks hurt sentiment and raised doubts about the pipeline.

    Major negative news that directly impacted investor confidence and valuation.

  • Governance pressure from top shareholder Top shareholder Artisan Partners demanded a board overhaul over dealmaking, with net debt at $39.4 billion and eight shareholders raising concerns. This adds uncertainty about strategy and capital allocation.

    Governance issues can weigh on stock price and investor trust.

  • Pipeline wins and licensing deals Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing for polymyalgia rheumatica, and Novartis signed licensing deals worth up to $8.1 billion plus acquired Sironax's brain-delivery platform, signaling continued investment in innovation.

    Positive pipeline news and deals support future growth despite recent failures.

Latest
▲2▼2

Novartis adds two big pipeline deals; board pressure and CAR-T pause persist

  • Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.

    These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.

  • Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.

    It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.

  • CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.

    It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.

  • EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.

    It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

▲2▼2

Novartis hit by three trial failures; pipeline doubts deepen

  • ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.

    New pipeline failure that directly adds to negative sentiment and future growth doubts.

  • Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.

    New deal that shows continued pipeline investment and a small positive counterweight.

  • EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.

    New regulatory win that broadens an existing product's label and provides a positive offset.

  • Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.

    New details on activist pressure and balance-sheet strain that affect investor confidence.

▼3▲1

Novartis hit by two trial failures, board pressure; MS drug offers hope

  • Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.

    This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.

  • Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.

    This is the biggest new negative event, causing a record share drop and directly impacting valuation.

  • Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.

    This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.

  • Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.

    This is the main positive counterweight, showing pipeline strength and potential to offset losses.

August 2026
▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

July 2026
▲4▼2

Novartis pipeline wins and earnings beat offset Entresto decline

  • EU approval for Itvisma gene therapy Novartis received EU approval for its Itvisma gene therapy, adding a new treatment option and reinforcing its position in advanced therapies. This expands the company's portfolio and offers a potential new revenue stream.

    This is a new regulatory win that supports future growth.

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval for Fabhalta in kidney disease, transitioning from accelerated approval. This validates the drug's efficacy and allows broader marketing, potentially boosting sales in a new indication.

    This is a new regulatory milestone that could drive revenue.

  • $1.5B Myricx Bio acquisition Novartis acquired Myricx Bio for $1.5 billion, adding a new asset to its pipeline. This strategic move aims to bolster future growth through external innovation.

    This is a new acquisition that expands the pipeline.

  • Q2 earnings beat with sales returning to growth Novartis reported Q2 earnings that beat expectations, with sales returning to growth despite Entresto's decline. This shows resilience and operational execution, reassuring investors about the company's trajectory.

    This is a new financial result that positively surprised the market.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% as generic competition entered the market, resulting in a $4 billion annual revenue hit. This significant loss pressures overall growth and profitability.

    This is a new negative development impacting financials.

  • UBS turns cautious on Novartis relative to peers UBS downgraded its view on Novartis, citing relative underperformance compared to AstraZeneca and Roche. This cautious stance may limit upside and affect investor sentiment.

    This is a new analyst action that could weigh on the stock.

  • High-stakes late-stage trials could add $10B+ but face failure risk Three late-stage trials (pelacarsen, remibrutinib, del-desiran) could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates meaningful pipeline uncertainty.

    This is a new analyst warning about pipeline risk.

▲2▼1

Novartis wins FDA label expansions, Q2 beat, but Entresto cliff and pipeline risk loom

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.

    This is a new regulatory win that directly boosts Novartis's revenue outlook.

  • Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.

    The earnings beat is a new event that shows the company's core business is performing better than expected.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.

    This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.

  • Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.

    This highlights the key risk and potential reward that will drive the stock's longer-term direction.

▲3▼1

Novartis advances gene therapy and oncology pipeline, but UBS turns cautious

  • EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.

    This is a concrete regulatory win that directly adds a new approved product and potential sales.

  • Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.

    This is a major strategic deal that bolsters the pipeline and signals growth investment.

  • ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.

    This points to a significant pipeline opportunity that could drive future revenue.

  • UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.

    This is a direct analyst opinion that could influence investor perception and relative performance.

Q2 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

June 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

AbbVie Inc (ABBV)

Q3 2026
▲2▼2

AbbVie Q3: Earnings Beat, Pipeline Wins, But Pricing and Trial Setbacks

  • Strong Q2 Earnings and Raised Guidance AbbVie's Q2 EPS and revenue beat estimates, and the company raised full-year revenue guidance. Skyrizi and Rinvoq now make up over 47% of revenue, offsetting Humira's decline. Neuroscience guidance also increased to about $12.7 billion.

    This shows the core business outperformed and management is optimistic about future growth.

  • Pipeline Progress and New Approvals AbbVie reported Phase 3 successes, received EU approvals, and gained FDA approval for JUVMO. These advances strengthen the company's drug portfolio and future revenue potential.

    New drug approvals and trial wins are key drivers of long-term growth and investor confidence.

  • EPCORE DLBCL-1 Trial Miss and Guidance Cut The EPCORE DLBCL-1 trial missed its endpoint, leading AbbVie to cut profit guidance. The stock dropped 4% on the news, highlighting pipeline risks.

    This was a major setback that directly hurt earnings expectations and investor sentiment.

  • Pricing Pressures and Competitive Threats Trump demanded U.S. price cuts, and J&J's oral psoriasis pill won Chinese approval. Apogee's $10.9 billion acquisition will dilute earnings until 2032, and oncology sales fell 2.8% as Imbruvica dropped 27.1%.

    These factors create headwinds for revenue and profitability, weighing on the stock.

September 2026
▲2▼2

AbbVie's Pipeline Wins Offset Apogee Dilution and Oncology Decline

  • Pipeline Momentum AbbVie reported multiple Phase 3 wins: etentamig for myeloma, Qulipta for menstrual migraine, and RINVOQ for vitiligo. EU approved Rinvoq for juvenile arthritis, and the FDA approved JUVMO for Parkinson's. Early-stage data for zumilokibart and ABBV-295 also showed promise.

    These pipeline successes signal future growth and strengthen AbbVie's competitive position.

  • Neuroscience Guidance Raised AbbVie raised its neuroscience revenue guidance to about $12.7 billion, with total revenue near $67.6 billion. This reflects confidence in its neuroscience portfolio and overall business strength.

    Higher guidance indicates management's optimism and potential for earnings growth.

  • Apogee Acquisition Dilutes Earnings The $10.9 billion Apogee acquisition will reduce earnings by $0.14 per share in 2026 and $0.46 in 2027, with profits not expected until 2032. This near-term dilution pressures the stock.

    The acquisition's dilution is a significant near-term headwind for earnings per share.

  • Oncology Sales Decline Oncology sales fell 2.8% as Imbruvica dropped 27.1% due to competition and IRA pricing. Newer drugs did not fully offset the decline, highlighting challenges in this segment.

    The decline in oncology revenue weighs on overall growth and profitability.

Latest
▲4

AbbVie's pipeline wins and new drug approvals drive growth outlook

  • FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.

    A major new drug approval directly expands AbbVie's revenue base and pipeline strength.

  • Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.

    Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.

  • ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.

    Early data support a potential best-in-class obesity drug, a major new growth opportunity.

  • RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.

    Late-stage data support a new indication for a major drug, enhancing its growth prospects.

▲3▼1

AbbVie's pipeline and label wins offset oncology and pricing headwinds

  • Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.

    New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.

  • Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.

    New regulatory approval directly expands a major growth drug's market and supports the bull case.

  • AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.

    New partnerships and a new approval show pipeline expansion and fresh revenue potential.

  • Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.

    A real counterweight: a key segment is shrinking due to competition and pricing pressure.

▲3▼1

AbbVie's pipeline and guidance wins offset Apogee dilution

  • Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.

    This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.

  • Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.

    This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.

  • Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.

    This is a new positive trial result that could expand the label and sales of an already fast-growing drug.

  • Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.

    This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

August 2026
▲3▼2

AbbVie's Skyrizi-Rinvoq Momentum Outweighs Pricing and Competition Risks

  • Skyrizi and Rinvoq Now Over 47% of Revenue AbbVie's two newer drugs, Skyrizi and Rinvoq, now make up more than 47% of total revenue and are expected to top $31 billion this year, more than offsetting declining sales of older Humira.

    This shows the core growth engine replacing Humira, a key positive force for the stock.

  • Neuroscience Guidance Raised and Pipeline Advances AbbVie raised its neuroscience revenue guidance to about $12.7 billion, and reported promising lung cancer data plus a European filing for a subcutaneous version of Skyrizi for Crohn's disease, strengthening future growth prospects.

    These pipeline and guidance updates point to new sources of revenue and expanded use of existing drugs.

  • Citadel Hedge Fund Boosts Stake 547% Citadel, a major hedge fund, increased its ownership stake in AbbVie by 547%, a sign that some large investors see strong value in the company despite recent concerns.

    A big institutional buyer can lift sentiment and signal confidence in the stock.

  • Trump Demands U.S. Price Cuts Within 60 Days President Trump demanded that AbbVie cut U.S. drug prices within 60 days, threatening its pricing power and adding regulatory uncertainty that could pressure revenue and profit margins.

    This is a new political risk that directly challenges AbbVie's ability to set prices in its largest market.

  • J&J's Oral Psoriasis Pill Wins Chinese Approval Johnson & Johnson's oral psoriasis pill Icotyde received approval in China, where 8.4 million patients could switch from injectable treatments like AbbVie's Skyrizi, posing a competitive threat in a key growth market.

    This new competition could slow Skyrizi's expansion and take market share.

▲3▼1

AbbVie's pipeline and franchise expansion offset profit-guidance cut

  • Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.

    Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.

  • New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.

    Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.

  • Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.

    A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.

  • J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.

    This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

▲2▼2

AbbVie's core drugs stay strong, but pricing pressure and pipeline setback weigh

  • Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.

    This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.

  • Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.

    This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.

  • Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.

    This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.

  • Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that could hurt future oncology revenue prospects.

July 2026
▲3▼1

AbbVie's Q2 Beat and EU Approvals Offset by Trial Miss and Profit Guidance Cut

  • EU Approvals Expand Drug Labels AbbVie won European approvals for TEPKINLY in follicular lymphoma, Boey for frown lines, and RINVOQ for alopecia areata, broadening its oncology, aesthetics, and immunology offerings. These label expansions can drive future revenue growth.

    New approvals are a key positive development that can boost investor confidence and future sales.

  • Q2 Earnings Beat and Guidance Raise AbbVie reported Q2 EPS of $3.65 and revenue of $16.99 billion, beating estimates. Management raised full-year revenue guidance by $300 million, citing strong growth in Skyrizi, Rinvoq, and neuroscience.

    The earnings beat and guidance raise show operational strength and support the bull case.

  • Voluntary Pricing Deals Reduce Uncertainty AbbVie entered voluntary most-favored-nation pricing agreements, which lessen regulatory uncertainty around drug pricing. This proactive step may stabilize the pricing environment and reduce political risk.

    Reduced regulatory uncertainty is a positive for the stock as it removes a potential overhang.

  • Trial Miss and Profit Guidance Cut The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint, hurting oncology sentiment. Additionally, a $291 million acquired IPR&D charge led AbbVie to cut full-year adjusted earnings guidance, sending shares down 4%.

    The trial failure and earnings guidance cut are significant negatives that pressured the stock.

▲2▼2

AbbVie beats Q2, raises revenue outlook, but full-year profit guidance cut

  • Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.

    This is the main new positive event this period, directly driving the stock's fundamental outlook.

  • Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.

    This is the key negative event this period, explaining the immediate stock drop and investor concern.

  • EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.

    This is a new regulatory win that expands the market for a key drug, supporting future sales.

  • Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that affects future growth prospects.

▲3▼1

AbbVie's pipeline wins approvals but faces trial setback and new competition

  • EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.

    New approval directly boosts AbbVie's oncology franchise and future sales.

  • EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.

    New product approval expands AbbVie's aesthetics portfolio and revenue potential.

  • Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.

    New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.

  • Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.

    New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Q2 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

June 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

▲2▼2

AbbVie hits 52-week high on Apogee deal and drug approvals, but China probe and slowing drug growth weigh

  • Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.

    This is the main reason the stock hit a new high and reflects the biggest new development this period.

  • US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.

    This is a new risk that could negatively affect the stock and was not in earlier reports.

  • Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.

    This is a new concern about the company's growth engine that could weigh on the stock.

  • Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.

    These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

▲3

AbbVie's $10.9B Apogee buy expands immunology pipeline

  • Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.

    This is the main new event driving ABBV's stock and future prospects.

  • Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.

    Shows the acquisition is financially manageable and not a strain.

  • Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.

    Highlights the trade-off investors are weighing.

  • Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.

    Analyst validation reinforces the market's positive reaction.

© 2026 MarketDXWhy